
Page#1
FINANCIAL STATEMENTS
Condensed Consolidated Statements of Earnings
Years ended June 30
2019 2018 2017
Dollars in millions, except share and per share data 
 
Net sales $ 6,214 $ 6,124 $ 5,973
Cost of products sold  3,486  3,449  3,302
 
Gross profit  2,728  2,675  2,671
Selling and administrative expenses  856  837  810
Advertising costs  612  570  599
Research and development costs  136  132  135
Interest expense  97  85  88
Other (income) expense, net  3  (3)  6
 
Earnings from continuing operations before income taxes  1,024  1,054  1,033
Income taxes on continuing operations  204  231  330
 
Earnings from continuing operations  820  823  703
Losses from discontinued operations, net of tax  —  —  (2)
 
Net earnings $ 820 $ 823 $ 701
 
Net earnings (losses) per share
 Basic
  Continuing operations $ 6.42 $ 6.37 $ 5.45
  Discontinued operations  —  —  (0.02)
 
 Basic net earnings per share $ 6.42 $ 6.37 $ 5.43
 
 Diluted 
  Continuing operations $ 6.32 $ 6.26 $ 5.35
  Discontinued operations  —  —  (0.02)
 
 Diluted net earnings per share $ 6.32 $ 6.26 $ 5.33
 
Weighted average shares outstanding (in thousands)
 Basic 127,734  129,293  128,953
 Diluted  129,792  131,581  131,566
|  |
THE CLOROX COMPANY  64  2019 INTEGRATED ANNUAL REPORT
Page#2
FINANCIAL STATEMENTS
Condensed Consolidated Balance Sheets
As of June 30
2019 2018
Dollars in millions, except share and per share data 
  
ASSETS 
Current assets
 Cash and cash equivalents $ 111 $ 131
 Receivables, net 631  600
 Inventories, net 512  506
 Prepaid expenses and other current assets 51  74
  
  Total current assets 1,305  1,311
  
Property, plant and equipment, net 1,034  996
Goodwill v 1,591  1,602
Trademarks, net 791  795
Other intangible assets, net 121  134
Other assets 274  222
  
Total assets $ 5,116 XXXX$ 5,060
  
LIABILITIES AND STOCKHOLDERS’ EQUITY 
Current liabilities
 Notes and loans payable $ 396 $ 199
 Accounts payable and accrued liabilities 1,035  1,001
 Income taxes payable 9  —
  
  Total current liabilities 1,440  1,200
Long-term debt 2,287  2,284
Other liabilities 780  778
Deferred income taxes 50  72
  
  Total liabilities 4,557  4,334
  
Commitments and contingencies 
Stockholders’ equity
Preferred stock: $1.00 par value; 5,000,000 shares authorized; none issued or outstanding —  —
Common stock: $1.00 par value; 750,000,000 shares authorized; 158,741,461 shares issued 
 as of June 30, 2019 and 2018; and 125,686,325 and 127,982,767 shares outstanding as of 
 June 30, 2019 and 2018, respectively 159  159
Additional paid-in capital 1,046  975
Retained earnings 3,150  2,797
Treasury shares, at cost: 33,055,136 and 30,758,694 shares as of June 30, 2019 and 2018, respectively (3,194)  (2,658)
Accumulated other comprehensive net (loss) income (602)  (547)
  
Stockholders’ equity 559  726
  
Total liabilities and stockholders’ equity $ 5,116 $ 5,060
  
|  |
THE CLOROX COMPANY  66  2019 INTEGRATED ANNUAL REPORT
Page#3
FINANCIAL STATEMENTS
Condensed Consolidated Statements 
of Cash Flows
Years ended June 30
2019 2018 2017
Dollars in millions 
 
 
 (As Adjusted*) (As Adjusted*)
Operating activities:
 Net earnings $ 820 $ 823  $ 701
 Deduct: Losses from discontinued operations, net of tax  —  —  (2)
 
 Earnings from continuing operations  820  823  703 
 Adjustments to reconcile earnings from continuing operations to net cash 
  provided by continuing operations:
 Depreciation and amortization  180  166  163
 Stock-based compensation  43  53  51
 Deferred income taxes  (20)  (23)  (35)
 Other  (29)  44  33
 Changes in:
 Receivables, net  (32)  (24)  (1)
 Inventories, net  (7)  (21)  (19)
 Prepaid expenses and other current assets  (6)  4  (5)
 Accounts payable and accrued liabilities  17  (47)  (34)
 Income taxes payable/receivable, net  26  1  12
 
Net cash provided by continuing operations  992  976  868
Net cash used for discontinued operations  —  —  (3)
 
Net cash provided by operations  992  976  865
 
Investing activities:
 Capital expenditures  (206)  (194)  (231)
 Businesses acquired, net of cash acquired  —  (681)  —
 Other 10  16  26
 
Net cash used for investing activities  (196)  (859)  (205)
 
Financing activities:
 Notes and loans payable, net  189  (214)  (125)
 Long-term debt borrowings, net of issuance costs  —  891  —
 Long-term debt repayments  —  (400)  —
 Treasury stock purchased  (661)  (271)  (183)
 Cash dividends paid  (490)  (450)  (412)
 Issuance of common stock for employee stock plans and other  147  45  75
 
Net cash used for financing activities  (815)  (399)  (645)
 
Effect of exchange rate changes on cash, cash equivalents and restricted cash  (2)  (3)  (1)
 
Net increase (decrease) in cash, cash equivalents and restricted cash  (21)  (285)  14
 
Cash, cash equivalents and restricted cash:
 Beginning of year  134  419  405
 
 End of year $ 113 $ 134 $ 419
 
Supplemental cash flow information:
 Interest paid $ 87 $ 75 $ 78
 Income taxes paid, net of refunds  207  245  347
Non-cash financing activities:
 Cash dividends declared and accrued, but not paid  133  123  108
*Adjusted to reflect the retrospective adoption of ASU No. 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash,” effective July 1, 2018.
|  |
THE CLOROX COMPANY  68  2019 INTEGRATED ANNUAL REPORT